Skip to content
B
BiotechEdge
Start Free Trial

Weekly Brief

Week of March 16, 2026

Top smart money signals, catalyst updates, and insider activity.

Share

What happened in biotech the week of March 16, 2026?

This week in biotech: 5 insider purchases. 4 catalyst outcomes including INCY. 5 high-conviction convergence signals. 6 catalysts expected in the next two weeks.

Insider Buys This Week

WVEBoughtRA CAPITAL MANAGEMENT, L.P. (Director) (3 transactions)
$ ---
AHCOBoughtOEP VII GP, L.L.C. (10% Owner) (4 transactions)
$ ---
PHRBoughtPale Fire Capital SE (10% Owner)
$ ---
MLYSBoughtRA CAPITAL MANAGEMENT, L.P. (Director)
$ ---
ZBIOBoughtFairmount Funds Management LLC (Director)
$ ---

Dollar amounts and insider titles available with a free trial.

Since Last FilingQ4 2025

WVEDown since Q4 2025
-- %
UTHRUp since Q4 2025
-- %

Exact price changes available with a free trial.

Catalyst Outcomes This Week

INCYPositivePhase 3 Readout
Retifanlimab
AMGNPositivePhase 3 Readout
AMG 510
AMGNPositivePhase 3 Readout
Inebilizumab
ALNYPositivePhase 3 Readout
Vutrisiran

Catalysts Ahead

2 catalysts this week in the next 30 days

PFEPhase 2 Readoutmaplirpacept (PF-07901801)
Apr 6, 2026
EXELPhase 2 ReadoutCabozantinib
Apr 12, 2026
INCYPhase 2 Readoutretifanlimab
Apr 14, 2026
PFEPhase 2 ReadoutMET233
Apr 15, 2026
REGNPhase 2 ReadoutFianlimab
Apr 17, 2026
PFEPhase 3 ReadoutDexmedetomidine
Apr 17, 2026
PFEPhase 3 ReadoutElranatamab
Apr 27, 2026
OCULPhase 3 ReadoutOTX-TKI (axitinib implant)
Apr 29, 2026
NBIXPhase 3 ReadoutValbenazine
Q2 2026
BIIBPhase 2 ReadoutBIIB122 225 mg
Apr 30, 2026
REGNPhase 2 ReadoutCemiplimab
Apr 30, 2026
IONSPhase 3 ReadoutEplontersen
Q2 2026
UTHRPhase 2 Readoutcyclophosphamide
Apr 30, 2026
DNLIPhase 2 ReadoutBIIB122 225 mg
Apr 30, 2026
RCUSPhase 2 ReadoutZimberelimab
Apr 30, 2026

High Conviction — Fund Convergence

KYMR9 fundsKymera Therapeutics Inc.
GPCR8 fundsStructure Therapeutics Inc.
RVMD6 fundsRevolution Medicines Inc.
PRAX6 fundsPraxis Precision Medicines, Inc.
CELC6 fundsCelcuity Inc.

Research This Week

ARGXPubMed
Successful treatment with efgartigimod as rescue therapy in acute attack of MOGAD: a case report.
RVMDPubMed
RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.
RCKTPubMed
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.
RCKTPubMed
Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial.
APLSPubMed
Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment.

Short Interest — Notable Changes

OCULSI Rising
-- %
UTHRSI Rising
-- %
PHRSI Rising
-- %
NBIXSI Rising
-- %
AHCOSI Rising
-- %
REGNSI Rising
-- %
WVESI Falling
-- %
MLYSSI Falling
-- %

Exact short interest %, share counts, and days to cover with a free trial.

Get this in your inbox every Monday

Plus dollar amounts, AI analyst context, watchlist alerts, and full dashboard access.

Start 14-Day Free Trial — $29/mo

Share this brief

Twitter/X|LinkedIn